Physician profile
Daniel John Parenti
NPI 1871594978
$34,129.45
in general payments reported to CMS, 2019-2025
12 companies · $4,855 in 2025
The $4,855 reported for 2025 was more than what 88% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $751 · 2020: $3,949 · 2021: $13K · 2022: $2,299 · 2023: $4,205 · 2024: $5,328 · 2025: $4,855.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $2,502 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,875.00 |
| Food and Beverage | $2,501.87 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $32,114.56 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $902.28 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Verona Pharma, INC. | $283.40 | 2025 | Ohtuvayre |
| Regeneron Healthcare Solutions, INC. | $229.95 | 2022-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.05 | 2019-2025 | Ofev, Jascayd |
| Novartis Pharmaceuticals Corporation | $115.05 | 2021-2025 | |
| Genentech USA, INC. | $69.73 | 2019-2025 | Xolair |
| Mylan Specialty L.P. | $58.29 | 2019 | |
| Genzyme Corporation | $56.62 | 2021-2024 | |
| Insmed, INC. | $33.21 | 2020-2025 | Arikayce |
| Takeda Pharmaceuticals U.S.A., INC. | $27.79 | 2024 | Aralast |
| Resmed Corp | $18.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Parenti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.